Rigel Q3 2023: Total revenue $28.1M, net loss narrows to $5.7M; TAVALISSE sales record $24.5M

RIGEL PHARMACEUTICALS INC

2023-Q3 EPS reported -$0.15 revenue$81,090,000

Q3 net loss $5.7M ($0.03/share) vs $19.0M ($0.11/share) in Q3 2022.
Total revenue $28.1M: TAVALISSE $24.5M (+27% YoY), REZLIDHIA $2.7M, collaboration $1.0M.
Cash and short-term investments $62.4M at Sep 30, 2023 vs $58.2M at Dec 31, 2022.
Phase 1b R289 (IRAK1/4 inhibitor) in LR-MDS enrolling third cohort; preliminary data expected mid-2024.
NECTAR trial fostamatinib arm ceased enrollment per DSMB recommendation; no safety concerns identified.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported third quarter ended September 30, 2023 results: revenue $28.1 million, net income net loss of $5.7 million, EPS $0.03 per basic and diluted share.

Period: third quarter ended September 30, 2023
Revenue: $28.1 million
Net income: net loss of $5.7 million
EPS: $0.03 per basic and diluted share
Result: reported results

Exact text from the filing

2 tm2329984d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update · Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of $2.7 million · New data on olutasidenib in mIDH1 relapsed or

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported nine months ended September 30, 2023 results: revenue $81.1 million, net income net loss of $25.8 million, EPS $0.15 per basic and diluted share.

Period: nine months ended September 30, 2023
Revenue: $81.1 million
Net income: net loss of $25.8 million
EPS: $0.15 per basic and diluted share
Result: reported results

Exact text from the filing

compared to a net loss of $60.0 million, or $0.35 per basic and diluted share, for the same period of 2022. For the nine months ended September 30, 2023, total revenues were $81.1 million, consisting of $68.1 million in TAVALISSE net product sales, $6.7 million in REZLIDHIA net product sales, $5.3 million in contract revenues from collaborations, and $1.0 million

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-115245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.